Vascepa Is Safe and Should Be Approved by End of Year, Amarin CEO Says

Aug.28 -- John Thero, Amarin Corp. chief executive officer, discusses the company's plans for its cardiovascular drug Vascepa. He speaks with Bloomberg's David Westin on "Balance of Power."

Bloomberg,